Navigation Links
Oncolytics Biotech Inc. Starts Patient Enrolment in U.K. Phase II Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin
Date:6/5/2008

CALGARY, June 5 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that that it has started patient enrolment in a Phase II clinical trial using intravenous administration of REOLYSIN(R) in combination with paclitaxel and carboplatin in patients with advanced head and neck cancers. The principal investigator is Dr. Kevin Harrington of The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust.

This trial is a 14-patient, single arm, open-label, dose-targeted, non-randomized trial of REOLYSIN(R) given intravenously in combination with a standard dosage of paclitaxel and carboplatin. Eligible patients include those with advanced or metastatic head and neck cancers that are refractory to standard therapy or for which no curative standard therapy exists. The primary objective of the Phase II trial is to measure tumour responses and duration of response, and to describe any evidence of antitumour activity. The secondary objective is to determine the safety and tolerability of REOLYSIN(R) when administered in combination with paclitaxel and carboplatin to patients with advanced or metastatic head and neck cancer.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I/II and Phase II human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit http://www.oncolyticsbiotech.com

This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the Company's expectations related to the U.K. Phase II combina
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... VIENNA , October 20, 2014 ... of gastrointestinal (GI) disorders and the delivery of care ... liver diseases and worrying inequalities in the provision of ... survey, which was commissioned by United European Gastroenterology (UEG), ... greater political and public awareness of the burden of ...
(Date:10/20/2014)... Local veterinary surgeon, Dr. Tim McCarthy is ... donor stem cells for dogs with osteoarthritis. Dr. McCarthy ... performed clinical stem cell therapy for 7 years. The ... a single injection of donor stem cells into one ... and inflammation in the treated joints. , Candidates ...
(Date:10/19/2014)... October 19, 2014 The Asian Automatic ... Asian with analysis and forecast of revenue. The Automatic ... to around $463.9 million by 2018, at a developing ... through the TOC of the Asian Automatic patient billing ... provided. This also provides a glimpse of the segmentation ...
(Date:10/19/2014)... According to market research report “Outdoor Wi-Fi ... gateways)]- Global Advancements, Forecasts and Analysis (2013 - ... market with analysis and forecasting of the global ... drivers and the restrains for this market with ... , Browse 65 market data tables and 69 ...
Breaking Biology Technology:Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 2Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 3Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 4Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 5Cascade Veterinary Referral Center Seeks Candidates for an Investigational Study of Stem Cells for Dogs with Arthritis 2The Asian Automatic patient billing market is estimated to grow to around $463.9 million by 2018 - New Report by MicroMarket Monitor 2The Asian Automatic patient billing market is estimated to grow to around $463.9 million by 2018 - New Report by MicroMarket Monitor 3Outdoor Wi-Fi Market (by Access Points, WLAN Controllers, Wireless gateways) Expected to Cross $37.2 Billion by 2018 - New Report by MarketsandMarkets 2Outdoor Wi-Fi Market (by Access Points, WLAN Controllers, Wireless gateways) Expected to Cross $37.2 Billion by 2018 - New Report by MarketsandMarkets 3Outdoor Wi-Fi Market (by Access Points, WLAN Controllers, Wireless gateways) Expected to Cross $37.2 Billion by 2018 - New Report by MarketsandMarkets 4
... security to residences and private offices with their state-of-the-art fingerprint recognition ... schools and the military is now accessible to the public. ... ... biometric technology used to enhance Hollywood films like Mission Impossible is ...
... (Nasdaq: NLTX ), today announced that Peter Strumph, ... in the Biotech Industry,conference on Thursday, September 4, at ... York City. Mr. Strumph will provide a company,overview and ... The presentation will be webcast live and can ...
... a leader in health,care quality management solutions for ... approved the company as a vendor for the ... will automate the collection and submission of clinical,information ... to,hand-write data collection worksheets or manually enter data ...
Cached Biology Technology:BIOLOCK(TM) USA Launches Affordable Fingerprint door Locks for Homes and Offices 2Nile Therapeutics to Present at BioCentury's NewsMakers in the Biotech Industry Conference 2MDdatacor Designated as Approved Vendor by CMS for Physician Quality Reporting Initiative 2
(Date:10/17/2014)... Rockville, MD – Accurate knowledge regarding Ebola is critical ... current risk of hazardous global outbreak and epidemic. The ... has launched a special issue, Ebola Virus and Public ... with necessary knowledge in this critical societal moment. ... Primer on Ebola for Clinicians . The primer was ...
(Date:10/16/2014)... William and Mary,s Virginia Institute of Marine Science ... Environmental Protection Agency to identify the streams and ... develop tools to help local governments and citizens ... critically on a dataset of tidal-marsh observations first ... with this historical baseline can today,s researchers accurately ...
(Date:10/16/2014)... women experienced improvements in vaginal atrophy, with no ... after 12 weeks of daily 10 milligram (mg) ... supplement previously shown to help relieve certain menopause ... reported in a poster at the North American ... "These data documented improved vaginal epithelium, without significant ...
Breaking Biology News(10 mins):EPA grant will help localities conserve headwater wetlands 2EPA grant will help localities conserve headwater wetlands 3S-equol supplements associated with improved measures of reproductive health in postmenopausal women 2
... a $407,163 National Science Foundation Early Career Development grant ... image of a patient,s deep tissue., Baohong Yuan, an ... at Arlington, said his process overcomes the challenge of ... analyze tissue more than a centimeter beneath the skin, ...
... How physicians view the causes of obesity may impact ... from a new study led by researchers at the ... the relationship between primary care physicians, beliefs about the ... They found that physicians who believed over consumption of ...
... for Experimental Biology (FASEB) is pleased to announce the ... Science. The competition solicited entries to demonstrate how federal ... economy of local communities in the United States. The ... group of graduate students from the Massachusetts Institute of ...
Cached Biology News:UT Arlington bioengineer to use hybrid imaging system to see deep tissue 2Physicians' belief about obesity causes impacts advice and care 2
... media for spontaneous ligand immobilization can be coupled ... antigen, or receptor to create an affinity matrix ... couple ligands via primary amines. Affi-Gel 10 gel ... 6.5 to 11; Affi-Gel 15 gel couples acidic ...
Mouse Anti-Human Killer Cell Immunoglobulin-like Receptor, Two Domains, Long Cytoplasmic Tail, 2 (KIR2DL2 (KIR2DL3 Monoclonal Antibody Family: Immunoglobulin Sub-Family: not assigned-Immunogl...
Chicken Anti-Human Stomatin-like 2 (STOML2 Polyclonal AntibodyNew Applications: ELISA, Western Blot...
Mouse Anti-Human Kallikrein 2 (Hk2)...
Biology Products: